BACKGROUND: Several studies have shown that antihypertensive monotherapy is commonly insufficient to control blood pressure (BP) in hypertensive patients and that concomitant use of ≥2 drugs is necessary in ∼50% of these patients. The combination of an angiotensin-converting enzyme (ACE) inhibitor and a diuretic, delapril plus indapamide (D + I), has been shown to be effective and tolerable, with no interaction between the 2 components. Another widely used combination of ACE inhibitor and diuretic is lisinopril plus hydrochlorothiazide (L + H). OBJECTIVES: The aims of this study were to confirm the antihypertensive efficacy and tolerability of the fixed combination of D + I in mild to moderate hypertension, and to compare its therapeutic efficacy and tolerability with that of L + H. METHODS: The antihypertensive efficacy and tolerability of a fixed combination of D + I (30-mg + 2.5-mg tablets once daily) or L + H (20-mg + 12.5-mg tablets once daily) in patients with mild to moderate hypertension were compared in a multinational, multicenter, randomized, 2-armed, parallel-group study. Eligible patients were aged 18 to 75 years and had a diastolic blood pressure (DBP) 95 to 115 mm Hg and a systolic blood pressure (SBP) ≤180 mm Hg, both measured in the sitting position. After a single-blind, placebo run-in period of 2 weeks, patients were randomized to receive 1 of the 2 treatments for a 12-week period. The primary efficacy end point was the BP normalization rate (ie, the percentage of patients with a sitting DBP ≤90 mm Hg) after 12 weeks of treatment. Secondary end points were as follows: (1) the responder rate (ie, the percentage of patients whose sitting DBP was reduced by ≥10 mm Hg from baseline or had a DBP ≤90 mm Hg after 12 weeks of treatment), (2) the percentage of patients with a DBP ≤85 mm Hg, and (3) changes in sitting SBP and DBP after 4, 8, and 12 weeks of treatment. RESULTS: A total of 159 hypertensive patients (88 women, 71 men) were randomized to receive D + I (44 women, 36 men; mean [SD] age, 53 [(11)] years) or L + H (44 women, 35 men; mean [SD] age, 55 [(10)] years). No significant between-group differences were found in any of the primary or secondary end points of the study. Both combinations induced a significant reduction in sitting DBP and SBP from baseline (P<0.001 for both groups at week 12), without significant differences between the groups. Five mild to moderate adverse drug reactions (ADRs) occurred in each treatment group. No patient dropped out of the study because of an ADR. CONCLUSION: This study showed no difference between D + I and L + H interms of antihypertensive efficacy or tolerability in patients with mild to moderate hypertension.

Chiesi Farmaceutici SpA Parma Italy

Clinic of Cardiovascular Disease University of Zagreb Zagreb Croatia

Department of Clinical Cardiology University of Prague Prague Czech Republic

Department of Internal Medicine D Campanacci University of Bologna Bologna Italy

Department of Internal Medicine University of Ljubljana Ljubljana Slovenia and

Zobrazit více v PubMed

Collins R, Peto R, MacMahon S. Blood pressure, stroke, and coronary heart disease: Part 2, Short-term reductions in blood pressure: Overview of randomised drug trials in their epidemiological context. Lancet. 1990;335:827–838. PubMed

Staessen J.A, Wang J.G, Thijs L. Cardiovascular protection and blood pressure reduction: A meta-analysis. Lancet. 2001;358:1305–1315. PubMed

Guidelines Subcommittee 1999 World Health Organization–International Society of Hypertension Guidelines for the Management of Hypertension. J Hypertens. 1999;17:151–183. PubMed

Hansson L, Zanchetti A, Carruthers S.G, for the HOT Study Group Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: Principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet. 1998;351:1755–1762. PubMed

Mancia G, Carugo S, Grassi G. Prevalence of left ventricular hypertrophy in hypertensive patients without and with blood pressure control: Data from the PAMELA population. Pressioni Arteriose Monitorate E Loro Associazioni. Hypertension. 2002;39:744–749. PubMed

Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) JAMA. 2002;288:2981–2997. PubMed

Rappelli A. Controlling hypertension: Lisinopril-hydrochlorothiazide vs captopril-hydrochlorothiazide. An Italian multicentre study. J Hum Hypertens. 1991;5(Suppl 2):55–57. PubMed

Bevilacqua M, Vago T, Rogolino A. Affinity of angiotensin I-converting enzyme (ACE) inhibitors for N- and C-binding sites of human ACE is different in heart, lung, arteries, and veins. J Cardiovasc Pharmacol. 1996;28:494–499. PubMed

Plante G.E, Dessurault D.L. Hypertension in elderly patients. A comparative study between indapamide and hydrochlorothiazide. Am J Med. 1988;84(Suppl 1B):98–103. PubMed

Gambardella S, Frontoni S, Pellegrinotti M. Carbohydrate metabolism in hypertension: Influence of treatment. J Cardiovasc Pharmacol. 1993;22(Suppl 6):S87–S97. PubMed

Ames R.P. A comparison of blood lipid and blood pressure responses during the treatment of systemic hypertension with indapamide and with thiazides. Am J Cardiol. 1996;77:12b–16b. PubMed

Poli G, Acerbi D, Ventura P, Hutt V. Pharmacokinetics of delapril and indapamide after single and repeated administration in healthy volunteers. Blood Press. 1994;3(Suppl):17S–25S.

Hutt V, Pabst G, Dilger C. Bioavailability and pharmacokinetics of a fixed combination of delapril/indapamide following single and multiple dosing in healthy volunteers. Eur J Drug Metab Pharmacokinet. 1994;19:59–69. PubMed

Rappelli A, Dessì Fulgheri P, Agabiti-Rosei E. Delapril and indapamide combination therapy in hypertensive patients: A double-blind randomized multicenter study. Blood Press. 1994;3(Suppl):34S–38S.

Leonetti G, on behalf of the DIMS investigators Delapril-Indapamide Multicenter Study (DIMS) Cardiologia. 1997;42(Suppl):401S–406S. [in Italian]

Rosei E.A, Rizzoni D. Evaluation of the efficacy and tolerability of the combination delapril plus indapamide in the treatment of mild to moderate essential hypertension: A randomised, multicentre, controlled study. J Hum Hypertens. 2003;17:139–146. PubMed

Rosiello G, Tozzi N, Sarno D. Safety and tolerability of long-term treatment with delapril-indapamide combination in patients with mild to moderate hypertension. Blood Press. 1994;3(Suppl):74S–79S.

Ambrosioni E, Borghi C, Costa F.V. Captopril and hydrochlorothiazide: Rationale for their combination. Br J Clin Pharmacol. 1987;23(Suppl 1):43S–50S. PubMed PMC